Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-667 pembrolizumab plus chemotherapy for slow early responder pediatric and young adult classical Hodgkin lymphoma
NL-OMON52677Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of pembrolizumab, sponsored by Merck & Co. Started Mar 2021; status: recruiting.
02
Drugs
Beyond the preview
Go deeper on NL-OMON52677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52677.